van Hoeven K H, Kovatich A J, Miettinen M
Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Diagn Cytopathol. 1998 Feb;18(2):93-7. doi: 10.1002/(sici)1097-0339(199802)18:2<93::aid-dc3>3.0.co;2-u.
Overlapping morphologic patterns that may be observed in goiter, follicular adenoma, and papillary carcinoma can limit the cytologic evaluation of the thyroid gland. In an attempt to develop a useful adjunctive test, the immunocytochemical reactivity of HBME-1, carcinoma antigen 19-9 (CA 19-9), and CD-15 (Leu-M1) was tested on 59 cell block preparations from fine-needle aspirations of the thyroid gland. HBME-1 monoclonal antibody was reactive in all 21 papillary carcinomas, in 4 of 18 adenomas, and in 5 of 20 goiters. CA 19-9 was identified in 13 of 21 carcinomas, 1 goiter, but none of the adenomas. CD-15 was present in 15 of 21 carcinomas, 1 goiter, and 1 adenoma. We conclude that HBME-1 is a sensitive marker of papillary thyroid carcinoma. CD-15 and CA 19-9 are less sensitive but more specific. This panel can be useful to help classify morphologically equivocal lesions. As with all immunocytochemical testing, caution must be exercised in the interpretation of results, and correlation made with morphologic and clinical data.
在甲状腺肿、滤泡性腺瘤和乳头状癌中可能观察到的重叠形态学模式会限制甲状腺的细胞学评估。为了开发一种有用的辅助检测方法，对59份甲状腺细针穿刺细胞块标本进行了HBME-1、癌抗原19-9（CA 19-9）和CD-15（Leu-M1）的免疫细胞化学反应检测。HBME-1单克隆抗体在所有21例乳头状癌、18例腺瘤中的4例以及20例甲状腺肿中的5例中呈阳性反应。CA 19-9在21例癌中的13例、1例甲状腺肿中被检测到，但在腺瘤中均未检测到。CD-15在21例癌中的15例、1例甲状腺肿和1例腺瘤中存在。我们得出结论，HBME-1是甲状腺乳头状癌的敏感标志物。CD-15和CA 19-9敏感性较低但特异性较高。该检测组合有助于对形态学上模棱两可的病变进行分类。与所有免疫细胞化学检测一样，在结果解释中必须谨慎，并与形态学和临床数据进行关联。
